We are advancing a broad pipeline of best-in-class proteins.
Our miniprotein pipeline embodies cutting-edge solutions leveraging novel mechanisms and targeted therapies to address high unmet medical needs.
Additionally, we are incubating two assets with promising applications in migraine prophylaxis and CNS medication, showcasing our commitment to broadening therapeutic horizons and addressing complex medical challenges.
Project Name
Phase
Project Initiation
Preclinical Research and Development
Clinical development
Hit generation
Lead generation
Development candidate identification
Preclinical development
Kv1.3
Kv1.3: partner with AOP Selective potassium channel inhibitor for chronic inflammatory diseases
New treatment for autoimmune diseases employing an immune-sparing mechanism of action
Selective blockade of Kv1.3 channels hinders chronic inflammatory processes via an immune-sparing mechanism
Description
Chronic inflammatory and autoimmune diseases place a heavy burden on society and all current medications are based on general immunosuppression. Chronically activated T-cells play a key role in the pathomechanism of these conditions. Unlike acutely activated T cells, these persistently activated cells exhibit a unique dependency on Kv1.3 potassium channels. Therefore, selective inhibition of Kv1.3 is a promising tool to treat chronic inflammatory and autoimmune diseases safely and effectively without general immunosuppression.
Our lead compound has demonstrated a robust in vivo effect in a rat dermatitis model.
CTXA
MMP2 inhibitor for cancer diagnosis and treatment
New antitumor medication from scorpion venom targeting Matrix Metalloproteinase-2 (MMP-2)
Asset Patented
Indication
Glioblastoma (GBM), melanoma
Mechanism of action
Specific targeting of MMP-2 overexpressing tumor cells
Description
In this project we develop new molecules for the therapy and diagnostics of MMP-2-expressing tumors, such as glioblastoma (GBM). Based on chlorotoxin (CTX), a natural miniprotein under clinical development, we developed a lead compound showing superiority in terms both affinity and selectivity compared to CTX. We filed a patent application covering a wide range of miniproteins (PCT/HU2021/050075). All claims of this application have been accepted in terms of all requirements of patentability in its International Preliminary Report on Patentability.
Our lead compound, applied as a targeting molecule in chimeric antigen receptor (CAR) T-cell therapy, has been shown to have strong effect in an in vivo glioblastoma (GBM) mouse model.
IL-11
Precision Therapy for Fibrosis: Selective IL-11 Inhibition with Enhanced Tissue Penetration
Targeting the IL-11 pathway to halt or reverse fibrosis with superior tissue access and minimal side effects
Indication
Idiopathic pulmonary fibrosis (IPF), sarcopenia
Mechanism of action
Selective blockade of IL-11 signaling, promoting fibrosis reversal through enhanced tissue penetration and precise target engagement
Description
Fibrosis affects millions globally, with pulmonary fibrosis impacting approximately 3-5 million patients worldwide, including those with idiopathic pulmonary fibrosis (IPF). Despite its prevalence, effective treatments remain scarce, highlighting the urgent need for targeted therapies.
IL-11 plays a critical role in the pathogenesis of IPF, where elevated levels are associated with increased fibrotic activity in lung tissue. Selectively blocking IL-11 signaling offers a promising approach to halt or reverse disease progression.
While antibody inhibitors of IL-11 are currently in clinical trials, our approach utilizes a miniprotein-based strategy powered by our AI-driven platform, AI-MPRO, which excels in addressing difficult targets. This platform enables the development of highly efficient miniproteins that not only exhibit high affinity and specificity but also ensure effective access to the target due to their compact and stable structure. This approach ensures excellent tissue penetration and minimizes side effects, positioning it as a superior solution for more effective and safer treatment of pulmonary fibrosis.
IL-6
Next-generation precision medicine against IL-6 trans-signaling for chronic inflammation
New treatment for chronic inflammatory and autoimmune diseases through selective inhibition of proinflammatory pathways
Indication
Chronic inflammatory and autoimmune diseases
Mechanism of action
Selective "Trans" IL-6 signaling specific therapy to target exclusively the pathogenetic proinflammatory pathway while sparing physiological immune functions
Description
Chronic inflammation is the key pathological process behind autoimmune diseases. Present therapies are based on non-specific immunosuppression and thereby associated with numerous side effects. Safe and effective treatment is possible via highly selective partial blockade of pathogenic IL-6 signaling. All current drugs on the market are monoclonal antibodies (mAbs) blocking IL-6 signaling globally leading to side effects like upper respiratory tract infections, neutropenia or acute pancreatitis. Our project employs an immune sparing mechanism of action by selectively targeting IL-6 trans-signaling while leaving the classical signaling and its physiological role untouched minimizng side effects and maximizing the efficiency.
Our platform specialized for miniprotein-based precision therapies aiming to provide a next-generation treatment with supreme specificity and extreme affinity.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
